Biotech Growth Trust (The) (LSE:BIOG) Cash-to-Debt : 0.27 (As of Sep. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Biotech Growth Trust (The) Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Biotech Growth Trust (The)'s cash to debt ratio for the quarter that ended in Sep. 2023 was 0.27.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Biotech Growth Trust (The) couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2023.

The historical rank and industry rank for Biotech Growth Trust (The)'s Cash-to-Debt or its related term are showing as below:

LSE:BIOG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: 0.17 Max: 0.27
Current: 0.27

During the past 13 years, Biotech Growth Trust (The)'s highest Cash to Debt Ratio was 0.27. The lowest was 0.06. And the median was 0.17.

LSE:BIOG's Cash-to-Debt is ranked worse than
73.78% of 1449 companies
in the Asset Management industry
Industry Median: 5.79 vs LSE:BIOG: 0.27

Biotech Growth Trust (The) Cash-to-Debt Historical Data

The historical data trend for Biotech Growth Trust (The)'s Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Biotech Growth Trust (The) Cash-to-Debt Chart

Biotech Growth Trust (The) Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

0.06

0.14

Biotech Growth Trust (The) Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Cash-to-Debt	Get a 7-Day Free Trial															0.20	-	-	0.14	0.27

Competitive Comparison of Biotech Growth Trust (The)'s Cash-to-Debt

For the Asset Management subindustry, Biotech Growth Trust (The)'s Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotech Growth Trust (The)'s Cash-to-Debt Distribution in the Asset Management Industry

For the Asset Management industry and Financial Services sector, Biotech Growth Trust (The)'s Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Biotech Growth Trust (The)'s Cash-to-Debt falls into.

Biotech Growth Trust (The) Cash-to-Debt Calculation

This is the ratio of a company's Balance Sheet Cash And Cash Equivalents to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Biotech Growth Trust (The)'s Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Balance Sheet Cash And Cash Equivalents	/	Total Debt
	=	Balance Sheet Cash And Cash Equivalents	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	2.772	/	(0	+	20.17)
	=	0.14

Biotech Growth Trust (The)'s Cash to Debt Ratio for the quarter that ended in Sep. 2023 is calculated as:

Cash to Debt Ratio	=	Balance Sheet Cash And Cash Equivalents	/	Total Debt
	=	Balance Sheet Cash And Cash Equivalents	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.133	/	(0	+	11.437)
	=	0.27

Biotech Growth Trust (The) (LSE:BIOG) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Biotech Growth Trust (The) Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Biotech Growth Trust (The)'s Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Biotech Growth Trust (The) (LSE:BIOG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » Biotech Growth Trust (The) PLC (LSE:BIOG) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

BIOGl:UK

Address

25 Southampton Buildings, London, GBR, WC2A 1AL

Website

https://www.biotechgt.com

Biotech Growth Trust (The) PLC is a United Kingdom-based investment trust. Its business objective is to provide its investors with capital appreciation by investing in the biotechnology industry around the world. The company portfolio comprises emerging biotechnology companies across North America, Europe, and Asia, of which North America accounts for the investment share.

Biotech Growth Trust (The) (LSE:BIOG) Headlines

No Headlines